XML 23 R13.htm IDEA: XBRL DOCUMENT v3.25.2
Subsequent Events
 6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]  
Subsequent Events

Note 8. Subsequent Events

 

ATM Offering

 

On July 18, 2025, Telomir Pharmaceuticals, Inc. (the “Company”), sold a total of 1,100,000 shares of its common stock, no par value, in block sales to institutional investors, at an average price of $2.6045 per share (a premium to the prior day’s close), through its at-the-market equity offering facility (the “Offering”). Gross proceeds from the Offering totaled approximately $2.9 million, prior to deducting fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the StockBlock platform. The Offering did not include any warrants.

 

Investment from Largest Shareholder

 

On May 19, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an agreement to raise $3 million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with the Company’s largest shareholder (See Notes 4 and 5). In July 2025, an additional 666,666 common shares were issued for $2 million received.